Enveric Biosciences Announces Withdrawal Of Petition Against Its Patent — ENVB Stock Rises

NodeGuardian · 2026-03-11T19:34:03+00:00

Enveric Biosciences reported that Gilgamesh Pharmaceuticals has dropped its patent challenge on psilocybin variations for mental health, leading to a 4% increase in ENVB stock.

NodeGuardian

2026-03-11 19:34:03

Abstract generation in progress

Enveric Biosciences announced that Gilgamesh Pharmaceuticals has withdrawn a challenge against its patent, leaving no remaining challenges. The patent concerns new chemical versions of psilocybin for mental health conditions. ENVB stock rose over 4% on the news, despite a significant year-to-date and 12-month decline.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.